Calcium Antagonists: A New Class of Therapeutic Agents

Overview

Journal Cardiovasc Dis

Specialty Cardiology & Vascular Diseases

Date 1981 Sep 1

PMID 15216199

Authors

Antonius Gunawan

Ali Massumi

Robert J Hall

Affiliations

Soon will be listed here.

Abstract

A new class of therapeutic agents, sharing inhibition of the slow calcium channel, will soon be available to the American patient. Selective action of these agents upon the atrioventricular node, the smooth muscle of coronary and peripheral arteries, and the contractility of cardiac muscle opens new vistas in cardiovascular pharmacology. Early release of these agents by the Federal Drug Administration for general use is urged, based upon the already wide and successful experience in the European and South American continents.

References

Henry P . Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem. Am J Cardiol. 1980; 46(6):1047-58. DOI: 10.1016/0002-9149(80)90366-5. View

Reimer K, Lowe J, Jennings R . Effect of the calcium antagonist verapamil on necrosis following temporary coronary artery occlusion in dogs. Circulation. 1977; 55(4):581-7. DOI: 10.1161/01.cir.55.4.581. View

Spurrell R, Krikler D, Sowton E . Effects of verapamil on electrophysiological properties of anomalous atrioventricular connexion in Wolff-Parkinson-White syndrome. Br Heart J. 1974; 36(3):256-64. PMC: 458827. DOI: 10.1136/hrt.36.3.256. View

Antman E, Stone P, Muller J, Braunwald E . Calcium channel blocking agents in the treatment of cardiovascular disorders. Part I: Basic and clinical electrophysiologic effects. Ann Intern Med. 1980; 93(6):875-85. DOI: 10.7326/0003-4819-93-6-875. View

Rosing D, Kent K, Maron B, Epstein S . Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status. Circulation. 1979; 60(6):1208-13. DOI: 10.1161/01.cir.60.6.1208. View

Livesley B, Catley P, Campbell R, Oram S . Double-blind evaluation of verapamil, propranolol, and isosorbide dinitrate against a placebo in the treatment of angina pectoris. Br Med J. 1973; 1(5850):375-8. PMC: 1588308. DOI: 10.1136/bmj.1.5850.375. View

Kawai C, Konishi T, Matsuyama E, Okazaki H . Comparative effects of three calcium antagonists, diltiazem, verapamil and nifedipine, on the sinoatrial and atrioventricular nodes. Experimental and clinical studies. Circulation. 1981; 63(5):1035-42. DOI: 10.1161/01.cir.63.5.1035. View

Gunther S, Muller J, Mudge Jr G, Grossman W . Therapy of coronary vasoconstriction in patients with coronary artery disease. Am J Cardiol. 1981; 47(1):157-62. DOI: 10.1016/0002-9149(81)90304-0. View

SCHAMROTH L, Krikler D, Garrett C . Immediate effects of intravenous verapamil in cardiac arrhythmias. Br Med J. 1972; 1(5801):660-2. PMC: 1787795. DOI: 10.1136/bmj.1.5801.660. View

10.

Vincenzi M, Morlino T, Allegri P, Barbieri E, Cappelletti F, De Lio U . Changes in cardiovascular function induced by verapamil in healthy subjects and in patients with ischemic heart disease. Clin Cardiol. 1981; 4(1):15-21. DOI: 10.1002/clc.4960040105. View

11.

Kaltenbach M, Hopf R, Kober G, Bussmann W, Keller M, Petersen Y . Treatment of hypertrophic obstructive cardiomyopathy with verapamil. Br Heart J. 1979; 42(1):35-42. PMC: 482109. DOI: 10.1136/hrt.42.1.35. View

12.

Camerini F, Alberti E, Klugmann S, Salvi A . Primary pulmonary hypertension: effects of nifedipine. Br Heart J. 1980; 44(3):352-6. PMC: 482410. DOI: 10.1136/hrt.44.3.352. View

13.

Rabkin S, Tomlinson C, CORBETT B, Cuddy T . Verapamil and supraventricular tachyarrhythmias: beneficial effect in patients with chronic pulmonary disease. Can Med Assoc J. 1980; 122(1):64-8. PMC: 1801604. View

14.

Sandler G, Clayton G, Thornicroft S . Clinical evaluation of verapamil in angina pectoris. Br Med J. 1968; 3(5612):224-7. PMC: 1986217. DOI: 10.1136/bmj.3.5612.224. View

15.

Singh B, Roche A . Effects of intravenous verapamil on hemodynamics in patients with heart disease. Am Heart J. 1977; 94(5):593-9. DOI: 10.1016/s0002-8703(77)80128-2. View

16.

Andreasen F, Boye E, Christoffersen E, Dalsgaard P, Henneberg E, Kallenbach A . Assessment of verapamil in the treatment of angina pectoris. Eur J Cardiol. 1975; 2(4):443-52. View

17.

Singh B, Collett J, Chew C . New perspectives in the pharmacologic therapy of cardiac arrhythmias. Prog Cardiovasc Dis. 1980; 22(4):243-301. DOI: 10.1016/0033-0620(80)90011-0. View

18.

Ferlinz J, Easthope J, Aronow W . Effects of verapamil on myocardial performance in coronary disease. Circulation. 1979; 59(2):313-9. DOI: 10.1161/01.cir.59.2.313. View

19.

Rosing D, Kent K, Borer J, Seides S, Maron B, Epstein S . Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. I. Hemodynamic effects. Circulation. 1979; 60(6):1201-7. DOI: 10.1161/01.cir.60.6.1201. View

20.

Maseri A, LAbbate A, Chierchia S, Parodi O, Severi S, Biagini A . Significance of spasm in the pathogenesis of ischemic heart disease. Am J Cardiol. 1979; 44(5):788-92. DOI: 10.1016/0002-9149(79)90198-x. View